Pituitary Tumor Diagnosis
Pituitary Tumor Diagnosis
The diagnosis is made by putting three lines of evidence together, not by a single test. A dedicated MRI of the pituitary with contrast shows the tumour and what it is touching. A panel of hormone measurements establishes whether the tumour is producing something in excess and whether the rest of the gland is still working. Formal visual field testing records what the optic nerves can still see. In the ordinary case no biopsy is needed before treatment — the scan, the hormones and the fields make the diagnosis.
Imaging: the scan that makes the diagnosis
A dedicated MRI of the pituitary with contrast is the imaging standard, and it answers the questions the whole plan depends on:
- Whether the tumour is there and where it sits — thin slices through the gland with contrast show a small tumour inside the gland, and show its relationship to the optic chiasm above and the cavernous sinus beside it. A routine brain MRI performed for another reason may not have covered the gland with the required slices, which is why a patient told their earlier scan was normal should ask which protocol it used.
- Which direction it has grown — upwards towards the chiasm, sideways into the cavernous sinus, or downwards into the sphenoid sinus. Each direction produces a different set of problems, and the direction determines whether surgery is approached from below and how much of the gland can be preserved.
- Whether the optic chiasm is displaced or compressed — the finding that makes treatment urgent rather than elective, and that is read together with the fields.
- What the healthy gland looks like — identifying the tissue that is still normal before treatment is what allows hormone replacement to be planned in advance rather than discovered to be needed afterwards.
No biopsy is needed before treatment in the ordinary case. Tissue is examined when the tumour is removed, and what it establishes is the tumour's type — which decides how it is followed and whether medication has a role — rather than a stage.
The hormone panel, and why each part matters
The hormone results are not a screening exercise; each axis is measured because it changes what is done:
- Prolactin — the single most informative measurement, because a prolactin-producing tumour is both the commonest functioning tumour and the one treated with medication first. A markedly raised level points towards a tumour that makes it; a mild rise can come from the stalk being compressed, which is a different situation and treated differently.
- The growth hormone axis — IGF-1 as the initial measure, with a glucose suppression test where acromegaly is suspected, since growth hormone is released in bursts and a single random level is not interpretable.
- The cortisol axis — an overnight dexamethasone suppression test, late-night salivary or serum cortisol, and ACTH, because establishing whether the body is producing too much cortisol and where the signal is coming from decides between treating the pituitary and treating the adrenal glands.
- Thyroid function — TSH together with free T4, read together rather than separately, because a low free T4 with a low or normal TSH points to the pituitary being the problem rather than the thyroid gland.
- The gonadal axis — FSH, LH, and oestradiol or testosterone, since loss of sex hormones affects fertility, bone density and wellbeing, and is treatable.
- The hormones that may be low — morning cortisol, free T4 and the sex hormones are checked precisely because a healthy gland can be failing, and because untreated cortisol deficiency is the part of this disease most likely to become an emergency.
The visual fields, and why they are measured
Formal perimetry is not a formality — it is a measurement that decides when treatment happens:
- What the test does — it maps the sensitivity of the peripheral field of each eye, by perimetry rather than by asking the patient whether their vision feels normal. It produces a printed record that can be compared from one visit to the next.
- Why the deficit is so characteristic — the crossing fibres from both eyes run immediately above the gland, so pressure produces a defect in the outer fields of both eyes. This pattern is one of the most specific signs in the whole condition.
- Why it is done before treatment, not only after — the baseline is what makes any later change interpretable. A defect found before treatment is the evidence for treating; a defect appearing afterwards is the evidence for reviewing the plan.
- What it does not measure — sharpness of central vision. A patient may read the chart perfectly with a substantial field defect, which is why central acuity alone is never used to rule the problem out.
How the tumour is measured and recorded
Two systems put the findings on record, and knowing them makes a report readable:
- Size, in millimetres — with the familiar division at about a centimetre between a microadenoma and a macroadenoma. The measurement matters less as an absolute number than as a change over time, and as the reason a particular approach was chosen.
- The direction of growth — upwards towards the chiasm, sideways into the cavernous sinus, downwards into the sphenoid sinus, or a combination. This is what determines whether sight is at risk and whether surgery can reach the tumour from below.
- The hormone, where there is one — recorded by name and by level, since for a functioning tumour the hormone is the disease, and the level before and after treatment is the measure of control.
- The function of the healthy gland — which axes are intact and which are failing, recorded before treatment so that replacement can be planned and any new deficiency afterwards attributed correctly.
- Why consistency matters — measurements taken on different scanners or by different methods drift by amounts larger than real change. Follow-up is best kept at one centre with the same protocol, and the images rather than the report are what get compared.
When genetic assessment is offered
For most patients no genetic test is needed, and its absence from the plan is not a gap. Assessment is offered in specific situations:
- An unusually young patient — inherited forms announce themselves early, so a pituitary tumour in a patient in their teens or twenties is a reasonable reason to ask.
- A family history — pituitary tumours in more than one relative, which raises the possibility of familial isolated pituitary adenoma or an AIP gene change.
- Other tumours that travel together — parathyroid, pancreatic or other endocrine tumours raise the possibility of multiple endocrine neoplasia type 1, and the pituitary tumour may be the first one found.
- What a confirmed diagnosis changes — lifelong scheduled imaging and blood tests for the pituitary and for any other gland involved; a lower threshold for investigating new symptoms; and genetic information that matters to relatives, which is best arranged through a genetics clinic.
What the diagnosis should establish
By the end of the assessment, these are the questions that should have been answered, and asking for them by name is a reasonable check:
- The identity of the hormone, if the tumour makes one, with the level recorded — or a statement that it produces nothing measurable.
- The size, and the direction in which it has grown — towards the chiasm, the cavernous sinus, or the sphenoid sinus below.
- What the visual fields show, on a printed record rather than in conversation.
- Which pituitary functions are intact and which are failing, in writing, before any treatment.
- What the options are — observation, medication, surgery, radiation — and what each would mean for the hormone and for the vision.
- What the follow-up would consist of, with the hormone tests, the imaging and the visual fields each given an interval, and the replacement hormones that would be needed after treatment identified in advance.
The reason to insist on all six is that this condition is managed over years, and each of these findings can alter what is done at a later stage. A plan that records them can be reviewed later on the basis of facts; one that records only a conclusion cannot.